Gene therapy has been developed predominantly as a tool to deliver corrective genetic DNA into cells to compensate for specific genetic mutations that cause cellular dysfunction and the consequent development of systemic disease [1] . However, gene therapy also can be used to introduce protective factors into the cells of healthy individuals, a process that has been termed "intracellular immunization" [2] . After exposure to human immunodeficiency virus type 1 (HIV-1), individuals whose lymphoid tissues are populated with adequate numbers of CD4 + T cells "intracellularly immunized" with molecular moieties encoding factors that inhibit HIV-1 replication may be sufficiently protected from infection to prevent the subsequent development of disease [3] . HIV-1 replication in cells may be blocked by the intracellular production of proteins that interfere with the activity of HIV-1 proteins that are critical during the early, as well as late, events of the virus life cycle postintegration phase [4] . For example, intracellular expression of RevM10, a dominant-negative competitor of Rev, inhibits Rev-mediated transport of structural HIV-1 RNA from the nucleus to the cytoplasm and protects transduced cells from HIV-1 infection [5] . Alternatively, infection by HIV-1 also may be prevented by the intracellular expression of proteins that interfere with the function of HIV-1-encoded enzymes that are pivotal for the establishment of infection, such as reverse transcriptase or integrase. For example, intracellular expression of single-chain variable fragments (SFvs) encoded by the cDNA of a monoclonal antibody directed against HIV-1 integrase (IN#33) significantly inhibited HIV-1 infection of transduced cells [6] . However, the advancement of intracellular immunization from promising in vitro studies to the clinical treatment of HIV-1-infected individuals has been hampered by the inability to readily evaluate the relative abilities of candidate genes to inhibit in vivo HIV-1 replication and thereby prevent HIV-1 infection. Major factors contributing to this limitation are the lack of vectors capable of efficiently delivering genes that encode protective proteins into primary CD4 + T lymphocytes and the absence of an animal model in which to examine and compare the protective capacity of intracellular immunization of different protective genes against in vivo challenge with HIV-1.
Here, we describe the development of a new approach to overcome these limitations and rapidly evaluate the in vivo efficacy of different candidate molecular moieties for intracellular immunization against HIV-1 infection. This new approach uses a novel vector system that efficiently delivers genes into cells in vivo, together with an HIV-1-susceptible animal model-severe combined immunodeficiency (SCID) mice implanted with human fetal thymic and liver tissue (thy/liv-SCID-hu mice) [7] [8] [9] . The new vector system we developed is based on recombinant simian virus (SV) 40 (rSV40), large T antigen-deleted SV40 that is replication defective, which efficiently delivers transgenes into hematopoietic progenitor and progeny cells that are consistently expressed in transduced cells [10] . Because the rSV40-derived vectors can be generated in titers of .10 11 infectious units (IU)/mL, which is 10-100-fold higher than those produced with simple oncoretroviral vectors, we postulated that these vectors should efficiently deliver molecular moieties that inhibit HIV-1 infection in vivo. The HIV-1-susceptible animal model we used is the thy/liv-SCID-hu mouse, which is constructed by implanting human fetal thymus and liver tissue under the murine kidney capsules, where the implanted tissue grows into a graft that closely resembles normal human thymus, exhibits long-term human T cell differentiation, and displays susceptibility to infection with HIV-1 [11] . We used this system to evaluate the in vivo capacity of anti-HIV-1 therapies to inhibit HIV-1 replication by examining their effects on the number of HIV-1-infected thymocytes in the human thymic graft [12] . Therefore, we postulated that we could evaluate the in vivo therapeutic efficacy of candidate anti-HIV-1 genes delivered by this vector using our thy/liv-SCID-hu mouse system [13] . In the present study, we investigated whether we could combine these 2 systems, rSV40-based vectors and thy/liv-SCID-hu mice, to develop a new approach that would permit us to evaluate the efficacy of candidate anti-HIV-1 genes delivered by intracellular immunization to successfully protect cells from in vivo HIV-1 infection.
Methods
Construction of thy/liv-SCID-hu mice. The thy/liv-SCID-hu mice were constructed by implanting human fetal thymic and liver tissue, obtained from 17-21-gestational-week human fetuses after the elective termination of pregnancy, into SCID mice (6-8 weeks old), as described elsewhere [11] . In brief, after SCID mice were anesthetized with pentobarbital (40-80 mg/kg), 10 pieces of syngeneic human fetal thymic and liver tissue were implanted under the left and right kidney capsules, and the tissue implanted initially would usually grow 20 times larger by 3 months after implantation.
Infection of thy/liv-SCID-hu mice with HIV-1. HIV-1 59 , a primary, R5-tropic, non-syncytium-inducing isolate, was derived from the peripheral blood mononuclear cells (PBMC) of a 17-month-old HIV-1-infected child, by coculture with phytohemagglutinin (PHA)-activated donor PBMC; was expanded by another round of coculture with PHA-activated PBMC; and then was divided into aliquots that were frozen in liquid nitrogen [11] . Thy/liv-SCID-hu mice were infected by intraimplant injection of 800 TCID 50 of HIV-1 59 in a volume of 50 mL. To control for variability due to the source of donor tissue and degree of reconstitution with human cells, each treatment group included mice engrafted with the same donor tissue and with similar quantities of human cells in their peripheral blood.
Titration of HIV-1-infected thymocytes in the human thymic implant by limiting dilution coculture. The level of HIV-1 infection of the human thymic implants was determined by quantifying the number of HIV-1-infected thymocytes present in the graft, using limiting dilution quantitative cocultures, as described elsewhere [11, 12] . This technique was used because it measures the number of cells capable of producing infectious HIV-1 [14] . Five-fold dilutions of human thymocytes isolated from the human thymic implants (range, 1 £ 10 6 to 3:2 £ 10 2 cells) were cultured in quadruplicate at 37 C in 24-well culture plates with PHA-activated donor PBMC (1:0 £ 10 6 cells) in 2.0 mL of RPMI 1640 medium containing fetal calf serum (10% vol/vol) and interleukin-2 (32 U/mL). The HIV-1 p24 antigen content of the culture supernatant was measured 1-2 weeks later, using the HIV-1 p24 core profile ELISA (Dupont-NEN). The lowest number of added human thymocytes that infected at least half the quadruplicate cultures with HIV-1 was determined and represented the frequency of thymocytes productively infected with HIV-1 present in the implant, reported as TCID 50 /10 6 thymocytes.
Production of rSV40-derived vectors. The SV40-based vector, SV(Aw), was generated from the pBSV(CMV)Aw plasmid encoding an SFv antibody directed against IN#33 [15] ; the control SV40-based vector, SV(HBS), was constructed from the pSV5(HBS) plasmid encoding the hepatitis B surface antigen, as described elsewhere [15] . Virus encoding IN#33 or hepatitis B surface antigen was produced by excising the viral genome from its carrier plasmid, recircularizing it, and transfecting it into COS-7 cells that provide the necessary Tag protein in trans, and then subsequently lysing the transfected cells. Virus stocks were amplified by infecting cultures of COS-7 cells with virus produced by transfection. Band purification of these stocks yielded titers of 10 11 IU/mL. Flow cytometric analysis. Thymocytes were harvested from the human thymic grafts of the thy/liv-SCID-hu mice and stained with fluorescein isothiocyanate-conjugated monoclonal antibody to human CD4 and phycoerythrin-conjugated monoclonal antibody to human CD8 (both from Becton Dickinson), as described elsewhere [11] . Expression of human CD4 and CD8 by thymocytes present in the thy/liv-SCID-hu mice was assessed by flow cytometric analysis using a FACScan cell analyzer with LYSIS-II software (Becton Dickinson). Lymphocyte gates were set on the basis of forward-and side-scatter profiles corresponding to gates set for control human lymphocytes from healthy adult volunteers.
Detection of transgene expression by immunocytochemical analysis. Expression of IN#33 in the transduced human thymocytes was detected by immunofluorescence, as described elsewhere [15] . A single-cell suspension was obtained from the human thymic implant and spotted onto slides, using a cytospin centrifuge. SupT1 cells, the CD4 + T cell line derived from a patient with non-Hodgkin's lymphoma, are efficiently transduced by rSV40-derived virus [15] and thus were used as a positive control for transduction and vector expression. Cells were fixed with ethanol at room temperature for 10 min and blocked overnight with 1% bovine serum albumin in PBS. The slides were incubated overnight with a 1:200 dilution of goat anti-mouse IgG (Nordic Immunology). After several washings, the slides were incubated with a 1:64 dilution of fluorescein isothiocyanate-labeled rabbit anti-goat IgG (Sigma) for 1 h at 37 C. After washing 5 times in PBS, coverslips were placed on the slides, and the slides were analyzed by epifluorescence microscopy. Controls for these studies included slides treated with normal IgG instead of antibody to mouse IgG, and SV(HBS)-infected cells treated with anti-mouse IgG.
Results
Efficient in vivo delivery of transgene by an rSV40-derived vector. To determine whether rSV40-derived vectors were capable of efficiently transducing cells after in vivo delivery, thymic implants of thy/liv-SCID-hu mice were injected with 5 £ 10 9 IU of SV(Aw). Four days later, the mice were killed, and a single-cell suspension of the thymic implant was obtained by gently teasing the graft apart, filtering the suspension through a sterile stainless steel mesh, and washing the cell suspension twice. Expression of the IN#33-encoding vector in the human thymocytes then was determined by epifluorescence microscopy. Representative photomicrographs displaying staining for IN#33 expression in thymocytes isolated from the human thymic graft after in vivo injection, compared with that of thymocytes from control uninjected human thymic implants and transduced and untransduced SupT1 cells, are shown in figure 1. To evaluate the length of time the integrasespecific SFv was expressed, 2 weeks after injection of human thymic implants in thy/liv-SCID-hu mice with SV(Aw) (n ¼ 2 mice) or with the control SV40-derived vector (n ¼ 2 mice), human thymic grafts were harvested, and the thymocytes were isolated and stained for the expression of IN#33 antibody. Although no staining was detected in the thymocytes from the human thymic grafts injected with the control SV40-derived vector, expression of IN#33 antibody was detected in the majority of the thymocytes from the human thymic implants injected with SV(Aw) (mean^SE, 85:25%^3:2%). Representative photomicrographs of the appearance of staining for IN#33 expression in thymocytes isolated from the human thymic graft after in vivo injection, compared with that of thymocytes from control uninjected human thymic implants and positive and negative controls, are shown in figure 1 . Thus, in vivo inoculation of the vector efficiently transduced human thymocytes with SV(Aw) and resulted in the prolonged in vivo expression by the human thymocytes of the anti-integrase SFv encoded by the IN#33 transgene.
In vivo transduction with SV(Aw) inhibits in vivo HIV-1 infection. To determine whether intracellular expression of IN#33 inhibited the infection of the human thymic grafts with HIV-1, we compared the levels of infection occurring in untransduced thymic grafts, thymic grafts transduced with SV(Aw), and thymic grafts transduced with a control SV40-derived vector after in vivo HIV-1 challenge. The human thymic implants of thy/ liv-SCID-hu mice were injected with either the SV(Aw) vector or the control SV(HBS) vector. One day later, these mice and an additional group of uninjected control mice were infected with HIV by direct inoculation of 30 mL of virus stock containing 800 TCID 50 of HIV-1 59 into the left human thymic and liver tissue implant. Direct injection of HIV-1 into the human thymic graft was used to deliver the viral challenge, to eliminate the possible contribution of variables that may be associated with the peripheral injection of HIV-1 into the mice. Two weeks later, biopsy samples of the human thymic implants of the mice were obtained, human thymocytes were isolated, and the level of HIV-1 infection in the human thymic grafts from each of the mice was determined by quantifying the number of HIV-1-infected thymocytes by performing quantitative coculture. The results of 3 separate experiments are shown in figure 2. The availability of only 2 mice for analysis in experiment 2 contributed to the higher variance observed in the level of HIV-1 infection detected in the human thymic implants from the SV(HBS)-injected mice. The data combined from these 3 separate experiments performed according to this protocol demonstrated that the number of HIV-1-infected thymocytes in the thymic grafts injected with SV(Aw) (mean^SE, 315^85 TCID 50 /10 6 thymocytes) was significantly lower (P ¼ :00005) than that of the thymic graft injected with SV(HBS) (mean^SE, 2375^381 TCID 50 /10 6 thymocytes). Thus, taken together, these results indicated that SV(Aw) administered in vivo efficiently transduced human thymocytes and protected them from in vivo HIV-1 infection.
Transduction with the SV(Aw) vector does not affect in vivo thymocyte maturation. The maturation process in the thymus involves transition of thymocytes from the immature CD4/CD8 double-positive stage to the more mature CD4 or CD8 singlepositive stage and can be assessed by examining the ratio of immature double-positive thymocytes to mature single-positive thymocytes [11] . It was possible that the decreased level of HIV-1 infection detected in the human thymic implants transduced with the SV(Aw) vector may have been due to a nonspecific toxic effect of the vector that suppressed human thymopoiesis in the graft, thereby decreasing the number of human thymocytes available for infection by HIV-1. Therefore, we investigated whether transduction with rSV40-derived vectors and expression of the IN#33 transgene affected human thymopoiesis in the human thymic implant. The relative proportions of the immature and mature thymocyte subpopulations were determined by quantifying the number of CD4 single-positive, CD8 single-positive, and CD4/ CD8 double-positive thymocyte subpopulations present in the biopsy specimens from the implants injected with SV(Aw) or SV(HBS) and then infected with HIV-1. As shown in figure 3 , there was no substantial difference between the fraction of mature single-positive and immature double-positive thymocytes populating the human thymic implants from thy/liv-SCID-hu mice injected with SV(HBS), compared with that present in the human thymic implants from thy/liv-SCID-hu mice injected with the SV(Aw) vector. This result demonstrated that thymopoiesis in the human thymic graft was not affected by transduction with the SV(Aw) vector and indicated that the inhibitory effect of transduction with the SV(Aw) vector on HIV-1 infection was not due to the cytotoxic effect of the vector on the human thymocytes present in the implant.
Discussion
In the present study, we investigated the feasibility of using a new system to evaluate the ability of intracellular immunization with genes that inhibit HIV-1 infection to confer in vivo protection from HIV-1 infection. To this end, we combined several systemsa transgene encoding IN#33, an SFv directed against HIV-1 integrase, intracellular expression of which protects cells from HIV-1 infection [6] ; a high-titered (. 10 9 IU/mL) rSV40-based vector delivery system that efficiently transduces lymphoid and myeloid cells [16] ; and a thy/liv-SCID-hu mouse model that is capable of being infected with HIV-1 [12] . We took advantage of the efficient transduction capacity of the rSV40 delivery system, described in our in our previous report [15] , that permitted sufficient delivery of an rSV40-based vector encoding IN#33, SV(Aw), into cultured SupT1 T cells to protect them from in vitro challenge with HIV-1 NL4-3 . The high-titered virus generated by the rSV40-derived vector system permitted us to effi- ] ). The human thymic implants of severe combined immunodeficiency mice implanted with human fetal thymic and liver tissue were injected with 5 £ 10 9 infectious units (IU)/mL of either the SV(Aw) vector or the control SV(HBS) vector. The next day, these mice and another uninjected group were infected by intraimplant injection with HIV-1 59 (800 TCID 50 ). In experiment 1, the human thymic implants were reinjected (5 £ 10 9 IU/mL) with the same recombinant SV40-derived vector 1 week later. Approximately 2 weeks later, biopsy samples were obtained from the human thymic implants, and the no. of HIV-1-infected thymocytes was quantified by quantitative coculture. The results of 3 separate experiments performed with 23 mice/group (experiment 1), 32 mice/group (experiment 2), or 5 mice/group (experiment 3) are shown; data are the mean no. (^SEM) of infected thymocytes (TCID 50 /10 6 thymocytes), determined by limiting dilution coculture of each group for each experiment. The mean no. of TCID 50 /10 6 thymocytes in the uninjected group of mice (n ¼ 2 mice in experiment 1 and n ¼ 3 mice in experiment 2) was 3125.
ciently deliver vectors after in vivo injection. The present study extends our previous in vitro studies by demonstrating that, after in vivo injection of the SV(Aw) vector into the thymic graft, IN#33 antibody was expressed intracellularly by the majority of the human thymocytes and that its expression was associated with significant in vivo protection of the implant from HIV-1 infection. This protection was indicated by the dramatically lower number of HIV-1-infected thymocytes detected by a limitingdilution assay in the human thymic implants injected with the SV(Aw) vector, compared with that detected in the human thymic grafts inoculated with a control SV40-derived vector. The marked reduction in the number of thymocytes capable of initiating productive HIV-1 infection observed in grafts injected with the SV(Aw) vector suggested that expression of the SFv targeted to HIV-1 integrase in thymocytes interfered with integration of the provirus and thereby reduced the number of thymocytes productively infected with HIV-1 after in vivo challenge. However, we cannot exclude the possibility that expression of the integrase-specific SFv did not prevent infection of the transduced thymocytes, but rather impaired their subsequent production of infectious HIV-1 after infection. Because genes can be readily inserted into the rSV40-expression vector used in these experiments, we can rapidly generate rSV40 encoding other candidate anti-HIV-1 genes and examine their in vivo efficacy, as described for SV(Aw) [15] . Thus, in the present report, we demonstrated the utility of this new model system in evaluating the in vivo efficacy of candidate molecular moieties that inhibit HIV-1 infection and/or replication for HIV-1-specific gene therapy. In addition, these data provide further support for the use of SV40-based vectors as efficient vehicles for in vivo gene delivery [17] .
The human thymic implants were not completely protected from HIV-1 infection by injection with the SV(Aw) vector. There are several possible explanations for this observation. We previously reported that transduction with the SV(Aw) vector did not completely protect cultured SupT1 T cells from infection after challenge with higher inocula of HIV-1 [15] . The somewhat incomplete protection conferred by the SV(Aw) vector may be due to the capacity of a higher inoculum of HIV-1 to induce sustained infection in the fraction of cells that were not transduced with the SV(Aw) vector. In addition, exposure to a higher infectious dose of HIV-1 may be able to overwhelm the inhibitory effect of the transgene that is mediated by its interference with HIV-1 integrase activity, an early stage in HIV-1 replication. Because the level of protection from HIV-1 challenge observed was comparable to the percentage of cells transduced, infection of the untransduced human thymocytes may account for the incomplete protection conferred by SV(Aw) injection. We found that multiple sequential transductions greatly improve gene delivery with rSV40-derived vectors in vitro [10] and in vivo [17] , suggesting that a greater level of in vivo anti-HIV-1 activity may also be achieved in this manner. More-complete protection may also be conferred by transduction with transgenes that block different stages in the viral replicative cycle. The effectiveness of this approach has been demonstrated by the potent inhibitory effects of treatment with combinations of antiretroviral drugs that target different steps of viral replication, such as reverse transcriptase and protease processing, to suppress viral replication to undetectable levels [18] . Although molecular therapeutic agents delivered by gene therapy would not completely inhibit HIV-1 replication in HIV-1-infected individuals, they may suppress HIV-1 infection sufficiently to lower the viral "set point" and thereby significantly affect the course of disease. It is possible that the resultant decrease in virus load would then lead to augmentation of the HIV-1-specific immune system and control the HIV-1 infection, as reported for individuals treated with highly active antiretroviral therapy who underwent supervised treatment interruption [19] .
The capacity to generate high titers of the rSV40-derived vectors permitted us to use an in vivo system to introduce the transgene and then challenge with HIV-1. This system differs from those used in most previous studies evaluating gene therapy, in which the target cells were removed from the in vivo environment, transduced and enriched for transduced cells ex vivo, and then reinfused. Furthermore, previous studies of HIV-1-specific gene therapy invariably evaluated the efficacy of the treatment by harvesting the transduced cells and then performing an in vitro challenge with HIV-1. For example, the thy/liv-SCIDhu mouse system has been used previously to evaluate one aspect of HIV-1-directed gene therapy, the capacity of CD34 + precursor cells transduced with an amphotropic retrovirus vector encoding RevM10, to differentiate into myeloid and lymphoid cells and continue to express the transgene [20] . However, in that study, efficacy of gene therapy was not determined by in vivo challenge of the mice with HIV-1 but by removing the implant from the mouse, expanding the thymocytes in culture, and then demonstrating that expression of the RevM10 construct protected the human thymocytes from HIV-1 infection after in vitro challenge [21] . In contrast, the present study describes a system in which HIV-1-susceptible cells were transduced and challenged in a fully in vivo environment. Thus, the present study describes the effective in vivo delivery of a transgene capable of significantly suppressing in vivo infection of cells with HIV-1. Combining the use of SV40-derived vectors expressing candidate transgenes that inhibit HIV-1 infection with our thy/liv-SCIDhu mouse model should permit the rapid evaluation of the efficacy of different gene therapeutic approaches to optimize the capacity of intracellular immunization to protect cells from HIV-1 infection.
